Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain technology beyond pharmaceutical distribution into commercial healthcare, healthspan, and wellness applications. The amended agreement supports patient-controlled health data access, monetization, and real-world asset tokenization across pharmacy, medical, laboratory, and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health, and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS' outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization. The companies stated that the agreement accelerates deployment of Datavault AI's technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
The expansion comes as healthcare increasingly adopts blockchain and AI technologies to address data interoperability, security, and patient ownership issues. By integrating Datavault AI's platform, which includes Web 3.0 capabilities for asset valuation and monetization, DataMEDS aims to create a system where patients can control and potentially profit from their health data. The technology also supports real-world asset tokenization, which could allow patients to tokenize health-related assets such as medical records or wearable device data.
Datavault AI's platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, and energy. The company's Information Data Exchange enables Digital Twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring.
The global health and wellness market, which includes digital health solutions, is projected to grow significantly, driven by increased consumer focus on health and the adoption of wearable devices and remote monitoring. Datavault AI's expansion into this sector positions it to capitalize on these trends, particularly as patients seek more control over their health data. The partnership with DataMEDS, which specializes in AI and blockchain for healthcare, provides a direct channel for deployment.
For more information on the full press release, visit https://ibn.fm/vBAxH. Additional updates on Datavault AI are available in the company's newsroom at https://ibn.fm/DVLT.
